BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) saw a large drop in short interest in the month of August. As of August 31st, there was short interest totalling 680,500 shares, a drop of 6.9% from the August 15th total of 731,200 shares. Based on an average daily volume of 558,500 shares, the days-to-cover ratio is currently 1.2 days.
BioXcel Therapeutics Stock Performance
Shares of BTAI opened at $0.64 on Thursday. BioXcel Therapeutics has a fifty-two week low of $0.53 and a fifty-two week high of $5.62. The company’s fifty day moving average is $0.85 and its 200 day moving average is $1.71. The stock has a market capitalization of $23.91 million, a PE ratio of -0.12 and a beta of 0.28.
BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.55. The business had revenue of $1.10 million for the quarter, compared to analysts’ expectations of $0.80 million. During the same quarter in the prior year, the company posted ($1.83) earnings per share. As a group, research analysts forecast that BioXcel Therapeutics will post -1.84 earnings per share for the current year.
Analysts Set New Price Targets
View Our Latest Analysis on BioXcel Therapeutics
Institutional Investors Weigh In On BioXcel Therapeutics
Several institutional investors have recently modified their holdings of BTAI. Point72 Asia Singapore Pte. Ltd. purchased a new stake in BioXcel Therapeutics during the 2nd quarter valued at $39,000. Armistice Capital LLC raised its stake in shares of BioXcel Therapeutics by 705.2% in the second quarter. Armistice Capital LLC now owns 2,987,000 shares of the company’s stock valued at $3,823,000 after acquiring an additional 2,616,027 shares during the period. XTX Topco Ltd lifted its holdings in shares of BioXcel Therapeutics by 49.0% in the 2nd quarter. XTX Topco Ltd now owns 46,503 shares of the company’s stock worth $60,000 after acquiring an additional 15,291 shares during the last quarter. Rosalind Advisors Inc. purchased a new position in shares of BioXcel Therapeutics during the 2nd quarter worth about $51,000. Finally, Vanguard Group Inc. grew its holdings in BioXcel Therapeutics by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 1,099,375 shares of the company’s stock valued at $3,100,000 after purchasing an additional 9,912 shares during the last quarter. 30.68% of the stock is owned by institutional investors.
About BioXcel Therapeutics
BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.
Featured Articles
- Five stocks we like better than BioXcel Therapeutics
- How to Calculate Inflation Rate
- How Much Can You Make in Stocks in One Month?
- What Are Growth Stocks and Investing in Them
- This Is the Top Large-Cap Stock Insiders Are Buying
- What is a Stock Market Index and How Do You Use Them?
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.